Cargando…
Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, many patients exhibit de novo or primary/early resistance. In addition, patients who initially respond...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758444/ https://www.ncbi.nlm.nih.gov/pubmed/33363040 http://dx.doi.org/10.3389/fonc.2020.610923 |
_version_ | 1783626941098622976 |
---|---|
author | Guo, Yijia Song, Jun Wang, Yanru Huang, Letian Sun, Li Zhao, Jianzhu Zhang, Shuling Jing, Wei Ma, Jietao Han, Chengbo |
author_facet | Guo, Yijia Song, Jun Wang, Yanru Huang, Letian Sun, Li Zhao, Jianzhu Zhang, Shuling Jing, Wei Ma, Jietao Han, Chengbo |
author_sort | Guo, Yijia |
collection | PubMed |
description | Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, many patients exhibit de novo or primary/early resistance. In addition, patients who initially respond to EGFR-TKIs exhibit marked diversity in clinical outcomes. With the development of comprehensive genomic profiling, various mutations and concurrent (i.e., coexisting) genetic alterations have been discovered. Many studies have revealed that concurrent genetic alterations play an important role in the response and resistance of EGFR-mutant NSCLC to EGFR-TKIs. To optimize clinical outcomes, a better understanding of specific concurrent gene alterations and their impact on EGFR-TKI treatment efficacy is necessary. Further exploration of other biomarkers that can predict EGFR-TKI efficacy will help clinicians identify patients who may not respond to TKIs and allow them to choose appropriate treatment strategies. Here, we review the literature on specific gene alterations that coexist with EGFR mutations, including common alterations (intra-EGFR [on target] co-mutation, TP53, PIK3CA, and PTEN) and driver gene alterations (ALK, KRAS, ROS1, and MET). We also summarize data for other biomarkers (e.g., PD-L1 expression and BIM polymorphisms) associated with EGFR-TKI efficacy. |
format | Online Article Text |
id | pubmed-7758444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77584442020-12-25 Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review Guo, Yijia Song, Jun Wang, Yanru Huang, Letian Sun, Li Zhao, Jianzhu Zhang, Shuling Jing, Wei Ma, Jietao Han, Chengbo Front Oncol Oncology Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, many patients exhibit de novo or primary/early resistance. In addition, patients who initially respond to EGFR-TKIs exhibit marked diversity in clinical outcomes. With the development of comprehensive genomic profiling, various mutations and concurrent (i.e., coexisting) genetic alterations have been discovered. Many studies have revealed that concurrent genetic alterations play an important role in the response and resistance of EGFR-mutant NSCLC to EGFR-TKIs. To optimize clinical outcomes, a better understanding of specific concurrent gene alterations and their impact on EGFR-TKI treatment efficacy is necessary. Further exploration of other biomarkers that can predict EGFR-TKI efficacy will help clinicians identify patients who may not respond to TKIs and allow them to choose appropriate treatment strategies. Here, we review the literature on specific gene alterations that coexist with EGFR mutations, including common alterations (intra-EGFR [on target] co-mutation, TP53, PIK3CA, and PTEN) and driver gene alterations (ALK, KRAS, ROS1, and MET). We also summarize data for other biomarkers (e.g., PD-L1 expression and BIM polymorphisms) associated with EGFR-TKI efficacy. Frontiers Media S.A. 2020-12-10 /pmc/articles/PMC7758444/ /pubmed/33363040 http://dx.doi.org/10.3389/fonc.2020.610923 Text en Copyright © 2020 Guo, Song, Wang, Huang, Sun, Zhao, Zhang, Jing, Ma and Han http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Guo, Yijia Song, Jun Wang, Yanru Huang, Letian Sun, Li Zhao, Jianzhu Zhang, Shuling Jing, Wei Ma, Jietao Han, Chengbo Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review |
title | Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review |
title_full | Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review |
title_fullStr | Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review |
title_full_unstemmed | Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review |
title_short | Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review |
title_sort | concurrent genetic alterations and other biomarkers predict treatment efficacy of egfr-tkis in egfr-mutant non-small cell lung cancer: a review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758444/ https://www.ncbi.nlm.nih.gov/pubmed/33363040 http://dx.doi.org/10.3389/fonc.2020.610923 |
work_keys_str_mv | AT guoyijia concurrentgeneticalterationsandotherbiomarkerspredicttreatmentefficacyofegfrtkisinegfrmutantnonsmallcelllungcancerareview AT songjun concurrentgeneticalterationsandotherbiomarkerspredicttreatmentefficacyofegfrtkisinegfrmutantnonsmallcelllungcancerareview AT wangyanru concurrentgeneticalterationsandotherbiomarkerspredicttreatmentefficacyofegfrtkisinegfrmutantnonsmallcelllungcancerareview AT huangletian concurrentgeneticalterationsandotherbiomarkerspredicttreatmentefficacyofegfrtkisinegfrmutantnonsmallcelllungcancerareview AT sunli concurrentgeneticalterationsandotherbiomarkerspredicttreatmentefficacyofegfrtkisinegfrmutantnonsmallcelllungcancerareview AT zhaojianzhu concurrentgeneticalterationsandotherbiomarkerspredicttreatmentefficacyofegfrtkisinegfrmutantnonsmallcelllungcancerareview AT zhangshuling concurrentgeneticalterationsandotherbiomarkerspredicttreatmentefficacyofegfrtkisinegfrmutantnonsmallcelllungcancerareview AT jingwei concurrentgeneticalterationsandotherbiomarkerspredicttreatmentefficacyofegfrtkisinegfrmutantnonsmallcelllungcancerareview AT majietao concurrentgeneticalterationsandotherbiomarkerspredicttreatmentefficacyofegfrtkisinegfrmutantnonsmallcelllungcancerareview AT hanchengbo concurrentgeneticalterationsandotherbiomarkerspredicttreatmentefficacyofegfrtkisinegfrmutantnonsmallcelllungcancerareview |